We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Laboratory Medicine and Nosocomial Infections: How Norway Reduces MRSA

By LabMedica International staff writers
Posted on 18 Feb 2010
Norwegian hospitals have had considerable success in their anti-methicillin-resistant Staphylococcus aureus (MRSA) efforts. More...


The country introduced strict control on antibiotic use that resulted in far fewer cases of the MRSA infections. An estimated 19,000 patients in U.S. hospitals died each year following MRSA infection, and observers are suggesting that the U.S. healthcare system could reduce those cases by replicating the Scandinavian country's control program.

How does Norway do it? Norwegian doctors prescribe fewer antibiotics than any other country, so people do not have a chance to develop resistance to them. Patients with MRSA are isolated and medical staff members who test positive stay at home. Doctors track each case of MRSA by its individual strain, interviewing patients about where they have been and who they have been with testing anyone who has been in contact with them.

"It's a very sad situation that in some places so many are dying from this, because we have shown here in Norway that methicillin-resistant Staphylococcus aureus can be controlled, and with not too much effort," said Jan Hendrik-Binder, Oslo's MRSA medical adviser. "But you have to take it seriously, you have to give it attention, and you must not give up."

Now a spate of new studies from around the world proves that Norway's model can be replicated with extraordinary success, and public health experts are saying deaths from MRSA are unnecessary.

In a small public hospital called the Queen Elizabeth Hospital Kings Lynn, NHS Trust (UK), about 100 miles outside of London (UK) microbiologist Prof. Lynne Liebowitz noticed the low Nordic MRSA rates, while the numbers in her hospital were increasing.

Prof. Liebowitz asked doctors to stop almost completely using two groups of antibiotics (fluoroquinolones and/or cephalosporins) known for provoking MRSA infections. One month later, MRSA rates were tumbling. In 2003, when the study started the hospital had 47 MRSA bloodstream infections. In 2008, they had one. This has been replicated at four other hospitals, all with the same results.

Related Links:
Queen Elizabeth Hospital Kings Lynn




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.